|
Apr 4
|
Traws Pharma Full Year 2023 Earnings: Beats Expectations
|
|
Apr 2
|
Traws Pharma Announces New Employee Inducement Grants
|
|
Apr 2
|
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
|
|
Mar 9
|
We Think Onconova Therapeutics (NASDAQ:ONTX) Needs To Drive Business Growth Carefully
|
|
Mar 8
|
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
|
|
Dec 12
|
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
|
|
Dec 8
|
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
|
|
Nov 28
|
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
|
|
Nov 7
|
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
|
|
Nov 2
|
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
|
|
Aug 13
|
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript
|
|
Aug 11
|
Q2 2023 Onconova Therapeutics Inc Earnings Call
|
|
Aug 10
|
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
|